News Headlines Article

U.S. panel votes against drug for rare cancer
USA Today

A panel of U.S. cancer experts voted against an experimental Merck drug for a rare type of cancer, saying the company’s trials did not show a meaningful benefit for patients. The Food and Drug Administration panel voted 13-1 against Merck’s ridaforolimus to help patients with sarcoma control their cancer after it is in remission. The vote is not binding, but the agency usually follows its recommendations.